AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24740134
Drug: AB103 low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AB103 low-dose (0.25 mg/kg)
Trial: 24740134
Drug: AB103 high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB103 high-dose
Trial: 24740134
Drug: AB103 low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AB103 low-dose
Trial: 24740134
Drug: AB103 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB103 (both doses)
Trial: 22995588
Drug: Two-Dimensional Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-Dimensional Conventional Radiation Therapy (2D‐CRT)
Trial: 18085144
Drug: Ear point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear point taping and pressing therapy
Trial: 18085144
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (Indomeixin enteric tablets)
Trial: 15129731
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (4 g daily)
Trial: 1524161
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 100 mg daily
Trial: 6337425
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 1000 mg daily
Trial: 31216027
Drug: High-dose PNE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PNE (N=20)
Trial: 31216027
Drug: Low-concentrated dose
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentrated dose PNE (N=20)
Trial: 31216027
Drug: Diluted low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diluted low-dose PNE (N=20)
Trial: 31216027
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (N=17)
Trial: 30641350
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.1, 0.2, 0.5, and 1.0 mg/kg)
Trial: 30641350
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (intravenous midazolam)
Trial: 26561332
Drug: RAISE protocol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RAISE protocol (Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease)
Trial: 26561332
Drug: Conventional Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Intravenous immunoglobulin (IVIG) protocol
Trial: 26561332
Drug: Positive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive group (patients with positive anti-YPT and/or anti-YPM antibodies)
Trial: 26561332
Drug: Negative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative group (patients without positive anti-YPT and/or anti-YPM antibodies)
Trial: 19835116
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Fluoxetine Hydrochloride at 20 mg daily
Trial: 15063441
Drug: Potassium canrenoate
RxNorm normalized name: Potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium canrenoate (intravenous)
Trial: 25966132
Drug: Concurrent radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent radiochemotherapy
Trial: 23386053
Drug: 0.3% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ropivacaine infusion at 4 mL/h for 64 hours
Trial: 23386053
Drug: 0.3% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% ropivacaine infusion
Trial: 21574787
Drug: Q500 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q500 (500 mg quercetin·day(‐1))
Trial: 21574787
Drug: Q1000 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q1000 (1000 mg quercetin·day(‐1))
Trial: 15569112
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg intravenously
Trial: 17272998
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg intravenously as infusion
Trial: 17272998
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg intravenously as bolus injection
Trial: 15585685
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment at a daily dose of 33 microg/kg (0.1 U/kg)
Trial: 15585685
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for >2 years before puberty
Trial: 15585685
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment for <2 years before puberty
Trial: 842813
Drug: Naloxone 0.1-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.1-0.2 mg i.v.
Trial: 842813
Drug: Naloxone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.2 mg i.m. (if required)
Trial: 24604835
Drug: Outpatient intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient intravenous cefepime 50 mg/kg (12 hourly)
Trial: 24604835
Drug: Inpatient intravenous
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient intravenous cefepime 50 mg/kg (12 hourly)
Trial: 22411278
Drug: Modified Melodic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Melodic Intonation Therapy (MMIT)
Trial: 15632666
Drug: Low progestin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low progestin oral contraceptives
Trial: 15632666
Drug: High progestin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High progestin oral contraceptives
Trial: 15632666
Drug: Active pill
RxNorm normalized name: Factive Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pill phase
Trial: 15632666
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill phase
Trial: 1329479
Drug: Lisinopril 5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5‐20 mg once daily
Trial: 1329479
Drug: Digoxin 0.125‐0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.125‐0.375 mg once daily
Trial: 28854500
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity laser therapy (HILT) combined with spinal decompression system (SDS)
Trial: 26862829
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg RBP-7000
Trial: 26862829
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg RBP-7000
Trial: 24829213
Drug: Measles vaccination
RxNorm normalized name: Measles vaccine (live)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccination (MV) in the presence of maternal antibody
Trial: 24829213
Drug: Measles vaccination
RxNorm normalized name: Measles vaccine (live)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles vaccination (MV) without maternal antibody
Trial: 24829213
Drug: Combined analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined analysis of measles vaccination (MV) with maternal antibody
Trial: 16263359
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy (IRT) using tungsten (188W) at doses of 18, 22, or 25 Gy
Trial: 16263359
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation therapy (IRT) using tungsten (188W)
Trial: 23108415
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.5 µg/kg/h)
Trial: 30109908
Drug: B-GOS® (2.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-GOS® (2.75 g/d)
Trial: 27001136
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy according to the Utrecht School (MTU)
Trial: 10833739
Drug: Fluoxetine (Prozac)
RxNorm normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (Prozac) with information about weight loss side effects
Trial: 10833739
Drug: Fluoxetine (Prozac)
RxNorm normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (Prozac) without information about weight-related side effects
Trial: 8335047
Drug: Single 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1 gram dose of ceftazidime with the induction of anaesthesia
Trial: 8335047
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g daily ceftazidime from induction of anaesthesia until removal of the urethral catheter (but ≤ 5 days)
Trial: 8335047
Drug: Ceftazidime-treated groups
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime-treated groups (both single-dose and multidose)
Trial: 3567048
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion at rates of 6.1 mg min‐1 and above
Trial: 3567048
Drug: Inosine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine infusion at dose rates up to 16.8 mg min‐1
Trial: 17167135
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine
Trial: 21979801
Drug: Sitaxsentan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan (100 mg/day)
Trial: 15051614
Drug: DHA (4.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (4.9 g/d)
Trial: 15051614
Drug: EPA (4.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (4.7 g/d)
Trial: 9772929
Drug: Anti Gp
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti Gp IIb‐IIIa (Reopro chimeric antibody, Abciximab®)
Trial: 16060203
Drug: Homeopathic medicine
RxNorm normalized name: Homeopathic medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic medicine
Trial: 2905500
Drug: Lormetazepam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (0.03 mg/kg IV) + ZK 93 426 (0.04 mg/kg IV)
Trial: 2905500
Drug: Lormetazepam (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam (0.03 mg/kg IV)
Trial: 2905500
Drug: ZK 93
RxNorm normalized name: ZK-93423
DrugBank: ZK-93423 (DB17063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK 93 426 (0.04 mg/kg IV)
Trial: 26372539
Drug: ICD‐9‐CM code
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD‐9‐CM code for dermatitis due to drug (693.0)
Trial: 26372539
Drug: ICD‐9‐CM code
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD‐9‐CM code for adverse reaction to drug (995.2)
Trial: 26372539
Drug: ICD‐9‐CM code
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD‐9‐CM code and E code combination
Trial: 26372539
Drug: Overall allergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall allergic drug reactions
Trial: 26372539
Drug: Frequency of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequency of allergic drug reactions
Trial: 23283449
Drug: Uniform multidrug
RxNorm normalized name: Eugenia uniflora whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniform multidrug therapy (U‐MDT) for leprosy
Trial: 23283449
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment regimen for leprosy
Trial: 17668537
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir suppressive therapy (1 g once daily for 6 months)
Trial: 17668537
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir episodic therapy (two 2-g doses separated by 12 hours at first sign of prodrome for 6 months)
Trial: 16265352
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with chemotherapy (weekly 5-fluorouracil and leucovorin 500 and 20 mg m(‐2), respectively)
Trial: 16265352
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with chemotherapy (daily x 5 Mayo Clinic schedule 425 and 20 mg m(‐2), respectively)
Trial: 16265352
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with chemotherapy (Mayo schedule)
Trial: 16265352
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (at onset of predefined symptoms)
Trial: 16265352
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with chemotherapy
Trial: 31002483
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment
Trial: 23888450
Drug: Glyceryl trinitrate
RxNorm normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate (GTN) ointment
Trial: 8672820
Drug: 20% lipid
RxNorm normalized name: Smoflipid 20% Lipid Emulsion for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% lipid emulsion amphotericin B (1 mg/mL)
Trial: 8672820
Drug: Conventional amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional amphotericin B (0.1 mg/mL) in dextrose 5% solution
Trial: 31833259
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) without interval debulking surgery
Trial: 22011907
Drug: briakinumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: briakinumab (200 mg at weeks 0 and 4 and 100 mg at week 8)
Trial: 22011907
Drug: briakinumab 100
RxNorm normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: briakinumab 100 mg every 4 weeks (q4-wk)
Trial: 22011907
Drug: briakinumab 100
RxNorm normalized name: briakinumab
DrugBank: Briakinumab (DB05459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: briakinumab 100 mg every 12 weeks (q12-wk)
Trial: 12481893
Drug: Hib conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugate vaccine
Trial: 11210884
Drug: Parenteral piperacillin/tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral piperacillin/tazobactam (3.375 g every 6 hours for 48 h)
Trial: 11210884
Drug: Parenteral piperacillin/tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral piperacillin/tazobactam plus topical piperacillin/tazobactam administered as a mouthwash immediately before surgery and once a day for 2 days postoperatively
Trial: 19015485
Drug: MK-677 25
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-677 25 mg
Trial: 7948820
Drug: IFN-alpha-2a therapy
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha-2a therapy
Trial: 3283625
Drug: Low-dose IFN
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IFN alpha-2c (1.2 x 10 IU/m x 28 days s.c. or lower)
Trial: 3283625
Drug: Daily IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IFN
Trial: 30188590
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL sucrose (25% in South Africa, 24% in Norway)
Trial: 30188590
Drug: 0.2 mL
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL sucrose (25% in South Africa, 24% in Norway)
Trial: 30188590
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL sucrose
Trial: 30188590
Drug: 0.2 mL
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL sucrose
Trial: 23228922
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (BB)
Trial: 23228922
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (BB) in high-risk patients (GRACE risk scores ≥121)
Trial: 23228922
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (BB) in high-risk patients (administered diuretics)
Trial: 23228922
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy (BB) in lower risk patients
Trial: 16416305
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GFJ) with 0.25 mg triazolam
Trial: 16416305
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GFJ) with 15 mg quazepam
Trial: 16416305
Drug: Control (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.25 mg triazolam without GFJ)
Trial: 16416305
Drug: Control (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (15 mg quazepam without GFJ)
Trial: 11188859
Drug: Older sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older sequential pattern (OS)
Trial: 11007407
Drug: no preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no preparation
Trial: 19345072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mirtazapine and paroxetine
Trial: 19345072
Drug: Non-responders on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders on monotherapy
Trial: 15722985
Drug: Oral polybacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polybacterial lysate suspension
Trial: 15722985
Drug: No-treatment clinical
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment clinical follow-up (control group)
Trial: 12069142
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol 400 micrograms (two tablets of 200 micrograms each)
Trial: 12069142
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets of vaginal placebo)
Trial: 27672029
Drug: Pentolinium (nicotinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentolinium (nicotinic ganglion blocker)
Trial: 22337287
Drug: PEG‐IFN2a (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN2a (90 mcg escalating to 180 mcg weekly for 48 weeks)
Trial: 22337287
Drug: Standard clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard clinical care (no further antiviral therapy)
Trial: 11896977
Drug: Topical repifermin
RxNorm normalized name: NEPIDERMIN
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical repifermin (recombinant human keratinocyte growth factor-2) applied for 12 weeks
Trial: 2851877
Drug: 5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/day ganciclovir
Trial: 2851877
Drug: 10 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg/day ganciclovir
Trial: 31630398
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide (50:50 mix with oxygen)
Trial: 31630398
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide (50:50 mix with oxygen) among parous women
Trial: 24532260
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract (PE) consumers (900 mg/day for 15 days)
Trial: 9815866
Drug: Aspirin 250
RxNorm normalized name: aspirin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 250 mg and Ticlopidine 500 mg/d (A+T group)